Dagens Industri is one of Sweden’s largest economy newspapers. On the 7th of December they are hosting Impact Summit Sweden in Stockholm, where Atley Co-Founder and CEO Milton Lönnroth has been invited to take part in a pannel discussion regarding the challenges DeepTech companies face when developing their innovations and scaling them globally.
In a LinkedIn post, Milton said the following:
“Very excited to have been invited to be one of the speakers at Dagens Industri Impact Summit Sweden this December!
The summit aims to bring entrepreneurs, innovation hubs, investors, and the public sector together to discuss how Swedish impact innovation can be nurtured locally, and scaled globally.
Here I will lift the topic of nuclearmedicine and targetedradionuclidetherapy, and my key message will be the following:
In order make the next frontier of oncology, Targeted Radionuclide Therapy, available to the citizens of Sweden, critical infrastructure for the production and distribution of radiopharmaceuticals must be expanded. Sweden therefore has two options:
Option 1: Invest now, and let Sweden play an important role in the development, clinical evaluation, and commercialisation of these potentially game changing cancer treatments.
Option 2: Wait for the rest of the world to innovate and then invest in the infrastructure to make such innovations available here.”
The event is free of charge, click here for more information and registration.
